Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 1/20 | 0.52 |
| ▸ | P2RY2 | P41231 | 8/20 | 0.50 |
| ▸ | P2RY4 | P51582 | 5/20 | 0.50 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.46 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.46 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.46 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.46 |
| ▸ | P2RY14 | Q15391 | 8/20 | 0.45 |
| ▸ | P2RY6 | Q15077 | 6/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15329290 | 0.91 | POLA1 (0.46) | POLA1P2RY2P2RY4SLC28A1SLC28A2 | |
| SCHEMBL30963978 | 0.90 | P2RY14 (0.45) | POLA1P2RY2P2RY4SLC28A1SLC28A2 | |
| SCHEMBL30963979 | 0.90 | P2RY14 (0.45) | POLA1P2RY2P2RY4SLC28A1SLC28A2 | |
| SCHEMBL31657660 | 0.88 | P2RY2 (0.52) | POLA1P2RY2P2RY4SLC28A1SLC28A2 | |
| SCHEMBL31598954 | 0.87 | P2RY2 (0.60) | POLA1P2RY2P2RY4SLC28A1SLC28A2 | |
| SCHEMBL20380343 | 0.87 | P2RY2 (0.42) | POLA1P2RY2P2RY4SLC28A1SLC28A2 | |
| SCHEMBL31552871 | 0.85 | P2RY2 (0.51) | POLA1P2RY2P2RY4SLC28A1SLC28A2 | |
| Phosphoric Acid SCHEMBL4575893 | 0.84 | SLC28A1 (0.53) | POLA1P2RY2P2RY4SLC28A1SLC28A2 | |
| Phosphoric Acid SCHEMBL20769291 | 0.84 | SLC28A1 (0.53) | POLA1P2RY2P2RY4SLC28A1SLC28A2 | |
| SCHEMBL31750991 | 0.84 | P2RY2 (0.49) | POLA1P2RY2P2RY4SLC28A1SLC28A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 906 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107341-A1 | COMBINATION THERAPY FOR TREATING HEPATITIS B VIRUS (HBV) INFECTION | Vir Biotechnology, Inc. (US) | 2026-05-21 | — | — | WO | claimed |
| EP-4745239-A1 | CFB INHIBITOR COMPOSITION AND USE THEREOF | Rigerna Therapeutics Co., Ltd. (CN) | 2026-05-20 | — | — | EP | claimed |
| EP-4714500-A2 | HEPATITIS B VIRUS (HBV) DSRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | Alnylam Pharmaceuticals, Inc. (US) | 2026-03-25 | — | — | EP | claimed |
| EP-3837366-B1 | HEPATITIS B VIRUS (HBV) DSRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS INC (US) | 2026-02-18 | — | — | EP | claimed |
| US-20260022161-A1 | COMBINATION HBV THERAPY | VIR BIOTECHNOLOGY INC (US) | 2026-01-22 | — | — | US | claimed |
| EP-4656656-A2 | COMBINATION HBV THERAPY | Humabs BioMed SA (CH) | 2025-12-03 | — | — | EP | claimed |
| US-20250320497-A1 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B VIRUS (HBV) INFECTION AND HBV-ASSOCIATED DISEASES | VIR BIOTECHNOLOGY INC (US) | 2025-10-16 | — | — | US | claimed |
| EP-4285929-B1 | COMBINATION HBV THERAPY | HUMABS BIOMED SA (CH) | 2025-10-08 | — | — | EP | claimed |
| US-20250304967-A1 | 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 (HSD17B13) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2025-10-02 | — | — | US | claimed |
| US-20250302951-A1 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS D VIRUS (HDV) INFECTION AND ASSOCIATED DISEASES | Vir Biotechnology, Inc. | 2025-10-02 | — | — | US | claimed |
| US-10934544-B2 | Factor XII (hageman factor) (F12), kallikrein B, plasma (fletcher factor) 1 (KLKB1), and kininogen 1 (KNG1) iRNA compositions and methods of use thereof | Alny lam Pharmaceuticals, Inc. (US) | 2021-03-02 | — | — | US | claimed |
| US-10933081-B2 | Myostatin iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-03-02 | — | — | US | claimed |
| WO-2020232024-A1 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B VIRUS (HBV) INFECTION | Vir Biotechnology, Inc. (US) | 2020-11-19 | — | — | WO | claimed |
| EP-3728593-A1 | HIGH MOBILITY GROUP BOX-1 (HMGB1) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | Alnylam Pharmaceuticals, Inc. (US) | 2020-10-28 | — | — | EP | claimed |
| US-20200308588-A1 | HIGH MOBILITY GROUP BOX-1 (HMGB1) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2020-10-01 | — | — | US | claimed |
| US-20200138847-A1 | MYOSTATIN IRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2020-05-07 | — | — | US | claimed |
| US-10640770-B2 | Hepatitis D virus (HDV) iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2020-05-05 | — | — | US | claimed |
| EP-3146049-B1 | ANGIOTENSINOGEN (AGT) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS INC (US) | 2020-02-26 | — | — | EP | claimed |
| WO-2020036862-A1 | HEPATITIS B VIRUS (HBV) dsRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2020-02-20 | — | — | WO | claimed |
| US-10478500-B2 | Compositions and methods for inhibition of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) gene expression | ALNYLAM PHARMACEUTICALS, INC. (US) | 2019-11-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022161-A1 | COMBINATION HBV THERAPY | NSUN2, RNMT, RNGTT | POLA1 382/4885P2RY2 1950/4885P2RY4 2314/4885 |
| US-20250304967-A1 | 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 (HSD17B13) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | HSD17B13, HSD17B3, HSD17B1 | POLA1 173/4885P2RY2 4830/4885P2RY4 4839/4885 |
| US-10934544-B2 | Factor XII (hageman factor) (F12), kallikrein B, plasma (fletcher factor) 1 (KLKB1), and kininogen 1 (KNG1) iRNA compositions and methods of use thereof | KLKB1, F12, F13A1 | POLA1 1572/4885P2RY2 4414/4885P2RY4 4323/4885 |
| US-20250302951-A1 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS D VIRUS (HDV) INFECTION AND ASSOCIATED DISEASES | DNTT, HAVCR2, POLRMT | POLA1 260/4885P2RY2 4593/4885P2RY4 4203/4885 |
| US-10478500-B2 | Compositions and methods for inhibition of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) gene expression | HAO1, HAO2, ACOX1 | POLA1 29/4885P2RY2 4341/4885P2RY4 4691/4885 |
| US-10640770-B2 | Hepatitis D virus (HDV) iRNA compositions and methods of use thereof | HAVCR2, EIF2AK2, CDV3 | POLA1 331/4885P2RY2 4849/4885P2RY4 4841/4885 |
| US-20250320497-A1 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B VIRUS (HBV) INFECTION AND HBV-ASSOCIATED DISEASES | IFNAR1, IFNG, HAVCR2 | POLA1 78/4885P2RY2 4217/4885P2RY4 4074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.